#pregnancy #arrhythmia #antiarrhythmic-drugs #maternal-arrhythmia #cardio-obstetrics

Arrhythmia in Pregnancy

Definition

Cardiac arrhythmias occurring during gestation and the immediate postpartum period encompass a wide spectrum from benign ectopy (the most common) to life-threatening ventricular arrhythmias. Management is governed by the dual-patient physiology: treatment decisions must simultaneously optimise maternal hemodynamics and minimise fetal harm. The 2023 HRS Expert Consensus Statement provides the first comprehensive dedicated international guidance for this field.

Key Concepts

Epidemiology

Overall prevalence in pregnancy-related hospitalisations: 68–166 per 100,000 admissions sources/arrhythmia-pregnancy-hrs-2023 (rating: very high)
Most common arrhythmias: premature atrial/ventricular ectopy (50–60% of those with palpitations; usually benign) sources/arrhythmia-pregnancy-hrs-2023
Sustained arrhythmias (68/100,000): AF 27/100,000, SVT 22/100,000, VT 16/100,000, VF 2/100,000 sources/arrhythmia-pregnancy-hrs-2023
In-hospital mortality with arrhythmia: 5.9% vs 0% without; perinatal complications 36.5% vs 21.8% sources/arrhythmia-pregnancy-hrs-2023
Arrhythmias more frequent in older mothers, Black women (116 vs 73/100,000), and those with structural heart disease or congenital heart disease sources/arrhythmia-pregnancy-hrs-2023
AF increasingly the most common newly diagnosed sustained arrhythmia, driven by rising maternal age, obesity, hypertension, and CHD survival sources/arrhythmia-pregnancy-hrs-2023
Only 10% of palpitation episodes during pregnancy have an arrhythmia documented on 24-hour Holter; most are benign sources/arrhythmia-pregnancy-hrs-2023

Pathophysiology of Arrhythmogenesis

Hemodynamic: Blood volume ↑50% (up to 100% in twin pregnancies) → chamber dilation → stretch-activated ion channels → spatial dispersion of refractoriness and shortened refractoriness sources/arrhythmia-pregnancy-hrs-2023
Hormonal: Estradiol and progesterone increase adrenergic receptor number/responsiveness; chamber enlargement lengthens reentrant pathways sources/arrhythmia-pregnancy-hrs-2023
Autonomic: Progressive shift from vagal to sympathetic dominance → HR ↑10–20 bpm → predisposes to new or worsened arrhythmias sources/arrhythmia-pregnancy-hrs-2023

Overarching Principles of Management

Multidisciplinary care (cardio-obstetrics team) is essential: cardiac electrophysiologist, MFM subspecialist, anesthesiologist, neonatologist, pediatric cardiologist (for fetal arrhythmias) sources/arrhythmia-pregnancy-hrs-2023
Hemodynamically significant arrhythmias should receive prompt, effective therapy (cardioversion, antiarrhythmic drug, or ablation) — care should not be compromised out of fear of fetal harm sources/arrhythmia-pregnancy-hrs-2023
Shared decision-making must account for risks/benefits to both mother and fetus sources/arrhythmia-pregnancy-hrs-2023
Genetic testing and counselling recommended for patients with suspected or known IAS sources/arrhythmia-pregnancy-hrs-2023

Procedural Considerations

Cardioversion

Safe and effective at all stages of pregnancy; same energy levels as non-pregnant patients sources/arrhythmia-pregnancy-hrs-2023
No modification of technique required; transthoracic impedance unchanged by pregnancy sources/arrhythmia-pregnancy-hrs-2023
Avoid electrode placement on breast tissue; sterno-apical for VT, antero-posterior for atrial arrhythmias sources/arrhythmia-pregnancy-hrs-2023
Fetal heart rate monitoring advised once fetal viability reached sources/arrhythmia-pregnancy-hrs-2023
Should never be withheld due to pregnancy when hemodynamic compromise is present sources/arrhythmia-pregnancy-hrs-2023

Catheter Ablation

Feasible during pregnancy; ideally deferred to after first trimester sources/arrhythmia-pregnancy-hrs-2023
Modern 3D mapping systems allow zero-fluoroscopy procedures sources/arrhythmia-pregnancy-hrs-2023
Typical SVT ablation: fetal radiation well below 50 mGy negligible-risk threshold for lifetime malignancy sources/arrhythmia-pregnancy-hrs-2023
Lead apron over pelvis: only 3% reduction in fetal radiation — most dose is scatter from maternal thorax, not direct beam; no meaningful protection sources/arrhythmia-pregnancy-hrs-2023
Complex ablation (e.g., refractory VT): requires cardio-obstetrics team prepared for urgent delivery

Device Implantation

ICD implantation: follows standard non-pregnant indications; safe with negligible fetal radiation; ideally post-first trimester but maternal safety takes priority sources/arrhythmia-pregnancy-hrs-2023
Pacemakers: implantable during pregnancy with zero/minimal fluoroscopy when indicated sources/arrhythmia-pregnancy-hrs-2023

Aortocaval Compression

IVC compression by gravid uterus begins at 20 weeks; severe at term; causes supine hypotensive syndrome sources/arrhythmia-pregnancy-hrs-2023
Left lateral tilt ≥30° or manual uterine displacement restores hemodynamics sources/arrhythmia-pregnancy-hrs-2023
Prolonged supine positioning is contraindicated from second trimester onwards sources/arrhythmia-pregnancy-hrs-2023

Anesthesia

Regional anesthesia preferred; general anesthesia for hemodynamic instability or cardiac procedures sources/arrhythmia-pregnancy-hrs-2023
Many perioperative drugs prolong QT interval (ondansetron, ketamine, sevoflurane, succinylcholine, epinephrine) — critical awareness in LQTS patients sources/arrhythmia-pregnancy-hrs-2023
Rapid sequence induction for general anaesthesia; smaller endotracheal tube (≤7.0 mm); difficult airway management sources/arrhythmia-pregnancy-hrs-2023

Antiarrhythmic Drug Principles in Pregnancy

Pharmacokinetic changes: increased volume of distribution, altered clearance — may require dose increases (especially in third trimester) sources/arrhythmia-pregnancy-hrs-2023
Select drugs with the longest record of safe use; use lowest effective dose; reevaluate periodically sources/arrhythmia-pregnancy-hrs-2023
DOACs: contraindicated in pregnancy and breastfeeding sources/arrhythmia-pregnancy-hrs-2023
Atenolol: best avoided (FDA former category D; fetal growth restriction risk higher than other beta-blockers) sources/arrhythmia-pregnancy-hrs-2023
Nadolol: highest breast milk concentration among beta-blockers; if breastfeeding, prefer propranolol or metoprolol (unless LQTS stability requires nadolol) sources/arrhythmia-pregnancy-hrs-2023
Amiodarone: reserve for refractory life-threatening cases; fetal thyroid dysfunction, growth restriction, neonatal adverse effects sources/arrhythmia-pregnancy-hrs-2023
Verapamil IV: causes significant maternal hypotension; last resort after adenosine and beta-blockers; avoid for fetal arrhythmias sources/arrhythmia-pregnancy-hrs-2023
Resources: MotherToBaby (mothertobaby.org), Reprotox, Teris; LactMed for lactation safety sources/arrhythmia-pregnancy-hrs-2023

Specific Arrhythmia Management

SVT

Acute: vagal manoeuvres → adenosine IV → beta-blockers IV → verapamil IV (last resort) → DC cardioversion if unstable sources/arrhythmia-pregnancy-hrs-2023
Prevention: digoxin, metoprolol, propranolol (robust safety records); atenolol avoided sources/arrhythmia-pregnancy-hrs-2023
WPW: flecainide or propafenone (block accessory pathway); avoid AV nodal blockers sources/arrhythmia-pregnancy-hrs-2023
Ablation: ideally pre-pregnancy; during pregnancy use zero-fluoroscopy after first trimester sources/arrhythmia-pregnancy-hrs-2023
Tachycardia-induced cardiomyopathy from focal AT: EF normalises with treatment; ablation if refractory sources/arrhythmia-pregnancy-hrs-2023

Atrial Fibrillation and Flutter

DC cardioversion first-line for hemodynamic compromise sources/arrhythmia-pregnancy-hrs-2023
Rate control: beta-blockers, digoxin, calcium channel blockers sources/arrhythmia-pregnancy-hrs-2023
Rhythm control: cardioversion ± antiarrhythmic; ibutilide (+ IV magnesium) safe; flecainide oral bolus an option sources/arrhythmia-pregnancy-hrs-2023
Anticoagulation: CHA₂DS₂-VASc applies; DOACs absolutely contraindicated; use LMWH or warfarin (Table 7 anticoagulation protocol as per mechanical valve management) sources/arrhythmia-pregnancy-hrs-2023
Catheter ablation: lower threshold for typical AFL; AF ablation generally deferred in pregnancy sources/arrhythmia-pregnancy-hrs-2023

Ventricular Tachycardia

Hemodynamically unstable: immediate DC cardioversion sources/arrhythmia-pregnancy-hrs-2023
Idiopathic (RVOT, fascicular): beta-blockers or verapamil; ablation if refractory sources/arrhythmia-pregnancy-hrs-2023
New VT in pregnancy: always evaluate for SHD, channelopathy, ACM as underlying cause sources/arrhythmia-pregnancy-hrs-2023

Bradycardia / Heart Block

Pacemaker implantation: standard indications; feasible with minimal/zero fluoroscopy sources/arrhythmia-pregnancy-hrs-2023
Congenital complete heart block (anti-Ro/SSB antibodies): serial fetal monitoring; dexamethasone controversial sources/arrhythmia-pregnancy-hrs-2023
Haemodynamically stable AV block with narrow QRS: conservative management at delivery sources/arrhythmia-pregnancy-hrs-2023

Cardiac Arrest in Pregnancy (ACLS)

Standard BLS/ACLS algorithms apply; coordinated multi-team response critical sources/arrhythmia-pregnancy-hrs-2023
From ~20 weeks: manual left uterine displacement during CPR (maintains supine position, facilitates airway/defibrillation) sources/arrhythmia-pregnancy-hrs-2023
No modification of chest compression hand position; standard defibrillation energy sources/arrhythmia-pregnancy-hrs-2023
IV access preferred above the diaphragm; interosseous humerus as alternative sources/arrhythmia-pregnancy-hrs-2023
Do not delay maternal defibrillation for fetal monitoring sources/arrhythmia-pregnancy-hrs-2023
Perimortem/resuscitative hysterotomy: initiate within 5 minutes for viable fetus; perform at site of arrest (no operating room needed); uterine evacuation often improves maternal hemodynamics independently sources/arrhythmia-pregnancy-hrs-2023

Inherited Arrhythmia Syndromes (IAS) — Overview

Risk: Pregnancies with maternal IAS have 8× higher fetal stillbirth rate and 2× higher miscarriage rate than normal population sources/arrhythmia-pregnancy-hrs-2023
Genetic counselling: essential preconception; trained genetic counsellors preferred sources/arrhythmia-pregnancy-hrs-2023
Delivery planning: three-tier risk-stratified framework (low/medium/high) based on recent events, QTc, arrhythmia type sources/arrhythmia-pregnancy-hrs-2023
See concepts/LQTS-Pregnancy-Management for LQTS-specific management
BrS: no clear increase in arrhythmic risk during pregnancy or postpartum in women; treat fever aggressively; avoid www.brugadadrugs.org contraindicated drugs sources/arrhythmia-pregnancy-hrs-2023
CPVT: maintain beta-blockers; add flecainide if recurrent; management follows non-pregnant recommendations sources/arrhythmia-pregnancy-hrs-2023

Contradictions / Open Questions

RCT evidence is almost entirely absent in this field; all drug safety and efficacy data are from registries, retrospective series, and case reports — LOE is predominantly C for most recommendations sources/arrhythmia-pregnancy-hrs-2023
Optimal anticoagulation strategy for AF in pregnancy is unresolved: current approach extrapolated from mechanical valve protocols; DOAC superiority in non-pregnant AF cannot be applied sources/arrhythmia-pregnancy-hrs-2023
Lead apron utility: Dogma of pelvic lead shielding is refuted by radiation physics data (only 3% dose reduction) — contrast with widespread clinical practice sources/arrhythmia-pregnancy-hrs-2023
Perimortem C-section timing: 5-minute goal is rarely achieved in practice; survival reported well beyond this window — suggests goal should be "as soon as possible" rather than a strict cutoff sources/arrhythmia-pregnancy-hrs-2023
Beta-blocker choice in LQTS breastfeeding: Nadolol is preferred for rhythm stability but concentrates in breast milk; no RCT comparing nadolol vs propranolol in this specific scenario sources/arrhythmia-pregnancy-hrs-2023
Fetal arrhythmia pharmacotherapy: No prospective randomised trial comparing flecainide vs digoxin vs sotalol has been conducted; all data from retrospective non-randomised studies sources/arrhythmia-pregnancy-hrs-2023

Connections

Related to concepts/Fetal-Arrhythmia — fetal arrhythmia management
Related to concepts/LQTS-Pregnancy-Management — LQTS-specific risk and management
Related to concepts/Cardio-Obstetrics — multidisciplinary team framework
Related to concepts/Antiarrhythmic-Drugs — drug safety profiles in pregnancy
Related to concepts/Torsades-de-Pointes — LQTS/drug-induced TdP in pregnancy
Related to concepts/Vasovagal-Syncope — most common syncope type in pregnancy
Related to concepts/Inappropriate-Sinus-Tachycardia — IST in pregnancy
Related to concepts/Tachycardia-Induced-Cardiomyopathy — from sustained focal AT
Related to entities/Long-QT-Syndrome — highest-risk IAS
Related to entities/Brugada-Syndrome — pregnancy management
Related to entities/CPVT — pregnancy management
Related to entities/Atrial-Fibrillation — most common sustained arrhythmia in pregnancy
Related to entities/Amiodarone — last resort; significant fetal toxicity
Related to entities/Flecainide — preferred for fetal SVT
Related to concepts/Adverse-Pregnancy-Outcomes — arrhythmias increase perinatal complications

Sources

sources/arrhythmia-pregnancy-hrs-2023 — 2023 HRS Expert Consensus (primary source)
sources/cv-pregnancy-aha-2020 — AHA 2020 Scientific Statement on CVD in Pregnancy
sources/cv-pregnancy-esc-2018 — ESC 2018 Guidelines for CVD Management in Pregnancy